Key Takeaways Fresenius Medical sees growth from FME25 savings, value-based care and the 5008X CAREsystem rollout.FMS' Value-Based Care hit EUR 2B in revenues in 2025, with 42% Q4 organic growth and breakeven profit.FMS faces a EUR 150-200M headwind from the TDAPA phase-out, flat U.S. volumes and China regulatory drag.Fresenius Medical Care AG & Co. (FMS) is well-positioned for growth, backed by strong profitability improvements from its FME25+ transformation program and growing momentum in value-based care ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style S ...

Core Insights - Fresenius Medical Care AG (NYSE:FMS) is recognized as one of the top German stocks to buy, with a strong performance in Q4 2025 [1] - The company reported an EPS of €1.14 for Q4 2025, a significant increase from €0.23 in Q4 2024, while revenue remained flat at €5.1 billion [1][3] Financial Performance - The management indicated that the earnings met internal targets, attributing success to a three-year focus on building resilience and disciplined operational and financial decisions [3] - A proposed dividend of €1.49 per share for 2025 earnings represents a 3% increase, with a payout ratio of approximately 33% [5] Future Outlook - Fresenius Medical Care AG aims to enhance profitability and plans to invest in future growth while addressing regulatory challenges [4] - The company projects a compound annual growth rate (CAGR) of 3% to 7% for operating income from 2025 to 2028 [4] Company Operations - Fresenius Medical Care AG operates a network of 3,601 kidney dialysis clinics, serving around 292,000 patients globally, and also manufactures dialysis machines [6]

Core Insights - Fresenius Medical Care AG & Co. (FMS) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 83 cents, exceeding the Zacks Consensus Estimate by 23.9%, with a year-over-year increase of 59% [1] - For the full year, the company achieved an EPS of $2.47, reflecting a 39.3% increase year over year [1] Revenue Details - FMS generated revenues of $5.88 billion (EUR 5,070 million) in the fourth quarter, surpassing the Zacks Consensus Estimate by 0.4%, although it represented a 0.3% decline year over year; at constant currency, revenues improved by 7.1% and were up 8% organically [2] - For the full year, total revenues reached $22.76 billion (EUR 19,628 million), indicating a growth of 1.5% year over year and 5.4% at constant currency, with organic growth of 8% [3] Segmental Performance - Care Delivery segment revenues decreased by 1.8% year over year but increased by 5.7% at constant currency, with organic growth of 7% [5] - Care Enablement segment revenues fell by 8.8% year over year, down 3.2% at constant currency and organically, primarily due to unfavorable currency impacts and lower volumes in China [8] - Value-Based Care segment revenues surged by 31.6% year over year, with a 42.4% increase at constant currency and organic growth, driven by a higher number of member months [9] Margin Analysis - FMS's gross profit improved by 9.3% year over year, with gross margin expanding by 240 basis points to 27.4% [10] - Adjusted operating income rose by 44.2% from the prior-year quarter, with the adjusted operating margin increasing by 430 basis points to 13.9% [10] Future Guidance - For 2026, FMS anticipates flat revenue growth and expects operating income to either decline or grow by mid-single-digit percentage points [11] - The company plans to expand its FME25+ program, projecting total savings of EUR 1.2 billion by the end of 2027 [13] Strategic Developments - FMS initiated a soft launch of its high-volume hemodiafiltration (HVHDF) capable 5008X CARE system in select U.S. clinics, with plans for a large-scale rollout to support top-line growth [15] - The company targets operating income growth at a CAGR of 3-7% between 2028 and 2030, aiming for a mid-teens operating income margin [16]

Core Insights - The company is transitioning from a turnaround phase to the 'FME Reignite' strategy, focusing on high-volume hemodiafiltration (HDF) to enhance long-term mortality reduction and operational efficiency [1] - Care Enablement in China is facing challenges due to volume-based procurement and regulatory changes, impacting earnings and delaying tenders [2] - The fourth quarter margin expansion was driven by higher-than-expected contributions from TDAPA-regulated products, with a significant performance step-up anticipated in 2025 due to the FME25+ transformation program [3] Group 1 - U.S. treatment volumes remain flat due to elevated mortality and missed treatments, but the company targets long-term growth of over 2% as mortality patterns normalize [1] - The FME25+ program aims for EUR 1.2 billion in total sustainable savings by the end of 2027, with EUR 400 million in additional savings identified [3] Group 2 - 2026 is expected to be a transition year with flat revenue expectations, primarily due to changes in risk contracting in Value-Based Care and the phasing out of temporary TDAPA benefits [3] - Management anticipates a regulatory earnings headwind of EUR 150 million to EUR 200 million, reflecting the transition of phosphate binders into the bundle and the expiry of ACA tax subsidies [3] Group 3 - The company plans to replace 20% of its U.S. clinic installed base with 5008X machines in 2026, incurring significant upfront training and rollout costs before realizing efficiency gains in 2027 [3] - Management introduced a 2028 aspiration of 3% to 7% operating income CAGR, noting that excluding 'regulatory noise' from TDAPA, the underlying growth trajectory is in the low teens [3]

Core Insights - Fresenius Medical Care AG & Co. KGaA reported significant improvements in profitability for the 2025 financial year, with a focus on a new long-term strategy called "FME Reignite" aimed at 2030 [3][4] Financial Performance - Earnings per share increased by 44%, driven by strong earnings and an accelerated share buyback program [1] - Organic revenue growth for 2025 was 8%, with operating income growing by 31% and net income rising by 82% [2] - The operating income margin improved to 11.3%, aligning with the midterm target band of 10% to 14% set three years prior [2][7] - The company generated EUR 2.7 billion in operating cash flow and repurchased EUR 586 million in shares during 2025 [9] Strategic Initiatives - The FME25 program exceeded its original savings target, achieving EUR 804 million against an initial target of EUR 500 million, with a goal of EUR 1.2 billion in sustainable savings by 2027 [7] - The rollout of the 5008X hemodiafiltration (HDF) therapy in the U.S. is highlighted as the largest product launch in the company's history, with positive feedback from patients and staff [11][13] 2026 Outlook - Management anticipates 2026 to be a transition year with broadly flat revenue and an operating income margin of 10.5% to 12% as temporary benefits phase out [5][17] - Expected headwinds include EUR 250 million to EUR 350 million from business growth, EUR 200 million to EUR 300 million in inflationary impacts, and EUR 150 million to EUR 200 million in regulatory challenges [17] - The company plans to invest EUR 100 million to EUR 150 million in the HDF rollout and IT platform harmonization [16] Segment Performance - All three operating segments contributed positively to 2025 performance, with Care Delivery benefiting from FME25+ savings and positive rate effects [8] - Value-Based Care reported 34% revenue growth, while Care Enablement faced challenges from regulatory policies in China [8] Additional Insights - The company plans to propose a dividend of EUR 1.49 for 2025, reflecting a 3% increase from 2024 [10] - Management noted that U.S. treatment volumes were flat in 2025, with expectations for gradual recovery to 2%+ growth [19]

Financial Performance - As of December 31, 2025, the company had cash and cash equivalents of €1,599 million, an increase from €1,180 million as of December 31, 2024[500]. - For the year ended December 31, 2025, the company reported revenue of €19,628 million, up from €19,336 million in 2024[503]. - Net cash provided by operating activities for 2025 was €2,681 million, representing 13.7% of revenue, an increase from 12.3% in 2024[503]. - Free cash flow for 2025 was €1,782 million, which is 9.1% of revenue, compared to 8.8% in 2024[503]. - The company's net debt as of December 31, 2025, was €9,196 million, down from €9,803 million in 2024[501]. - The net leverage ratio improved to 2.5 in 2025 from 2.9 in 2024[501]. - Capital expenditures in 2025 amounted to €899 million, accounting for approximately 5% of total revenue[512]. - The company anticipates capital expenditures between €0.8 billion and €1.0 billion in 2026, focusing on organic growth and new production facilities[516]. - The company utilized €1,403 million in net cash for financing activities in 2025, primarily for debt repayment and share buybacks[518]. - Days Sales Outstanding (DSO) improved to 59 days as of December 31, 2025, down from 63 days in 2024[507]. - The total dividend payments for 2025, 2024, and 2023 were €423 million, €349 million, and €329 million, respectively[522]. - As of December 31, 2025, the company had available liquidity sources totaling €3.307 billion, including a syndicated credit facility of €2 billion and other unused lines of credit of €1.307 billion[525]. - Total assets decreased by 8% to €31.0 billion as of December 31, 2025, from €33.6 billion in 2024, primarily due to a 9% negative impact from foreign currency translation[530]. - The equity ratio decreased to 46% at December 31, 2025, compared to 47% in 2024, driven by a decrease in shareholders' equity and treasury stock purchases[531]. - The return on invested capital (ROIC) increased to 5.0% at December 31, 2025, from 3.5% in 2024, due to higher operating income and reduced costs related to Legacy Portfolio Optimization[531]. - The company plans to propose a dividend of €1.49 per share for 2025, resulting in an expected total payment of approximately €416 million[528]. - The principal financing needs for 2026 include bond repayments and share repurchases, expected to be covered by cash flow and existing credit facilities[529]. Research and Development - The global R&D strategy focuses on developing innovative products and therapies for renal care, including digital health solutions and AI-supported care models[539]. - In 2025, the Renal Research Institute undertook several R&D initiatives aimed at enhancing patient care through personalized and precision medicine[541]. - The Clinical Research team supported commercialization efforts, including clinical trials and collaborations with start-ups to promote innovation[540]. - In 2025, over 15,300 U.S.-based patients utilized the NxStage portable HHD system, an increase from more than 14,500 in 2024, driven by the introduction of the FDA-approved GuideMe software[554]. - The multiFiltratePRO acute dialysis machine study enrolled 31 patients across ten U.S. clinics, confirming safety and effectiveness, with registration submission for the citrate solution expected in December 2025[545]. - The introduction of the 5008X CAREsystem with HVHDF in the U.S. marks a significant innovation milestone, with initial therapies conducted in 2025 and a commercial launch planned for 2026[560][561]. - Approximately 58,000 therapy prescription programs were delivered remotely in 2025, with over 7.7 million patient treatments digitally transmitted[558]. - The Renal Research Institute's AI applications aim to enhance precision nutrition strategies and improve home dialysis adoption through predictive modeling[549]. - The CE mark for hemoperfusion mode of the multiFiltratePRO platform was obtained in 2025, expanding its capabilities for ICU staff[570]. - Fresenius Medical Care's digitalization efforts focus on therapy data management systems and improving workflow efficiency for healthcare professionals[565]. - The company aims to reduce environmental impact by optimizing the material consumption of its 5008 bloodline portfolio and introducing PVC-free Biofine® foil for dialysate bags[567][572]. - The MFT PRO Adult Study confirmed the performance and safety of the multiFiltratePRO device for continuous kidney replacement therapy, meeting KDIGO targets[546]. - The company strengthened global research partnerships in 2025, enhancing innovation in kidney care through initiatives like the MONDO International Network[550]. - The Apheresis Pathogen Reduction Device (APRΞD) received CE MDR certification in August 2024, with commercial launch planned for January 2026[573]. - Fresenius Kidney Care's R&D expenditure was €158 million in 2025, down from €183 million in 2024, representing 4% of healthcare product revenue[580][583]. - The total number of patents held by the company decreased to 7,890 in 2025 from 9,529 in 2024, with 67 additional patent families produced in 2025[580][583]. - The company doubled its manufacturing capacity and output for heart and lung business in 2025, enhancing supply reliability for extracorporeal life support systems[575]. - The successful regulatory approval of synchronized cardiac support therapy in 2025 represents a significant advancement in ECMO therapy, improving patient outcomes[576]. - The Ready4 multiFiltratePRO AR training application was expanded in 2025 to enhance clinician education with immersive 3D models and dynamic visuals[574]. - The ReferralReady program launched in 2023 aims to streamline the transplant referral process, improving efficiency and increasing patient placements on the kidney transplant waitlist[578][579]. - As of December 31, 2025, the company employed 1,488 R&D staff, an increase from 1,384 in 2024, with over 940 based in Europe[581][583]. - The semi-automated workflow of the ReferralReady program saves dialysis social workers two hours of administration per referral, enhancing their capacity to assist patients[584]. - The Xenios 2.0 console, launched in April 2025, improves connectivity for multiFiltratePRO devices, streamlining data management for healthcare providers[577]. Management and Governance - Ms. Sara Hennicken appointed as Chief Financial Officer of Fresenius SE on September 1, 2022, with prior experience in investment banking and corporate finance[598]. - Mr. Martin Fischer became Chief Financial Officer of the Company on October 1, 2023, previously Head of Finance for Siemens Healthineers' Diagnostics division[611]. - Dr. Jörg Häring appointed to the Management Board responsible for Legal, Compliance, and Human Resources as of June 1, 2024, with extensive experience in legal and compliance roles[613]. - Ms. Helen Giza serves as Chief Executive Officer and Chair of the Management Board, previously held key positions at Takeda Pharmaceuticals and Management AG[610]. - Mr. Craig Cordola appointed as Chief Executive Officer of Care Delivery as of January 1, 2024, with nearly 30 years of experience in the healthcare industry[612]. - Dr. Marcus Kuhnert served as Chief Financial Officer of Merck KGaA until June 30, 2023, bringing significant experience in finance and procurement[600]. - Ms. Pascale Witz has held executive positions at Sanofi S.A. and GE Healthcare, currently serving as president of PWH Advisors[602]. - Mr. Shervin J. Korangy has extensive experience in healthcare and investment, currently a senior advisor to TPG Inc.[599]. - The Management Board members are appointed for a maximum term of five years, with a standard retirement age of 65[609]. - The Company has a diverse Supervisory Board with members from various sectors, enhancing strategic oversight and governance[604]. Compensation and Performance Targets - The overall target achievement for the short-term variable compensation component (STI) for the fiscal year was between 56.01% and 101.58%[624]. - The target achievement for revenue growth in 2023 was reported at 5.5%, with a target of 0.3%[627]. - Net income growth for 2023 was reported at (25.2)%, with a target of (25.9)%[627]. - The return on invested capital (ROIC) for 2023 was adjusted to 2.7%, with a target of 2.8%[627]. - The target achievement for the allocation made in 2023 under the Management Board Long-Term Incentive Plan (MB LTIP 2020) will be determined based on performance in fiscal years 2023, 2024, and 2025[625]. - The compensation system for Management Board members was approved by the Company's 2024 AGM with a majority of 87.58% of the votes cast[636]. - The FME Reignite strategy was implemented in the fiscal year, maintaining the existing compensation system[633]. - Compensation for Management Board members remained unchanged compared to the previous year[632]. - The Company reported a significant adjustment of €71 million and €45 million for operating income and net operating profit after tax, respectively, for the fiscal year 2023 due to one-time costs related to the FME25+ program[629]. - The Management Board members' compensation is designed to align with the Company's strategic objectives and long-term value creation[622]. - The target total direct compensation for the fiscal year 2025 consists of 29% base salary, 31% Short-Term Incentive (STI), and 40% Long-Term Incentive (LTI) for Management Board members[644]. - The STI target amount for fiscal year 2025 is set at a multiplier of 1.05, while the LTI allocation amount is set at a multiplier of 1.35 for all Management Board members[644]. - The maximum compensation for the Chairperson of the Management Board (CEO) is €12,000 K or $12,975 K, while the maximum for the Care Delivery segment CEO is €9,500 K or $10,272 K[660]. - The total compensation of each Management Board member is capped at 150% for STI and 400% for LTI allocations[655][656]. - The compensation structure includes a significant performance-based component, with 71% of the target total direct compensation being performance-based[646]. - The LTI allocation amount for the Chairperson can range from 105% to 200% of the base salary, while for other members it ranges from 105% to 150%[643]. - The Supervisory Board conducts both horizontal and vertical comparisons to ensure the appropriateness of the compensation system[651][653]. - The compensation awarded or due in the fiscal year includes fixed and variable components, with fixed components comprising base salary, fringe benefits, and pension commitments[666][667]. - The Supervisory Board has the authority to withhold or reclaim variable compensation in cases of misconduct or non-compliance[663]. - There were no instances in the fiscal year that warranted the use of caps or maximum compensation adjustments by the Supervisory Board[665]. - The short-term incentive (STI) target amount for fiscal year 2025 is set at 105% of the base salary for each Management Board member[673]. - The STI is based on four performance targets: 20% revenue, 40% operating income, 20% net income, and 20% sustainability-related performance[677]. - For the fiscal year, the group revenue target was €19,399 million, with actual revenue reported at €19,628 million, achieving 126.96% of the target[685]. - The operating income target for the group was €2,136 million, with actual reported income of €1,827 million, achieving 69.80% of the target[685]. - The net income target was set at €1,199 million, with actual net income reported at €978 million, achieving 53.44% of the target[685]. - The sustainability target for the STI achieved an overall score of 115%, with "Patient Satisfaction" at 120% and "Employee Satisfaction" at 110%[694]. - The Net Promoter Score (NPS) for "Patient Satisfaction" was set at a target of 71, with an actual score of 73[691]. - The Global Employee Engagement Score (GEES) target was set at 65, with an actual score of 66[693]. - The STI is paid out in cash in the year following the year of target achievement[678]. - The financial performance targets are adjusted for certain effects to ensure comparability with operational performance[681].

Financial Data and Key Metrics Changes - Fresenius Medical Care achieved a group margin of 11.3% for 2025, driven by all three operating segments, landing well within the target margin band for the year [6][7] - Operating income growth for 2025 reached 27%, marking a significant increase compared to previous years [7][12] - The company reported a strong fourth quarter with organic revenue growth of 8% and earnings growth of 53%, resulting in a margin of 13.9%, a 430 basis points increase over the prior year [12][18] Business Line Data and Key Metrics Changes - Care Delivery in the U.S. experienced same-market treatment growth that was broadly flat, while international markets delivered solid 1.7% same-market treatment growth [12][13] - Care Enablement revenue decreased by 3%, primarily due to negative impacts from volume-based procurement and regulatory policies in China [23] - Value-Based Care achieved a break-even operating income for 2025, a notable improvement from a historically loss-making position [16][22] Market Data and Key Metrics Changes - The company faced challenges in China due to regulatory pressures and tender delays, impacting revenue and earnings development [16][23] - The U.S. market saw a significant contribution from phosphate binders under TDAPA regulations, which positively affected revenue [14][20] Company Strategy and Development Direction - Fresenius Medical Care launched its new 2030 strategy, FME Reignite, aimed at accelerating growth and driving profitability improvements [5] - The company is focusing on the rollout of the 5008X CAREsystem in the U.S., which is expected to enhance operational efficiencies and patient outcomes [28][29] - The FME25+ transformation program has delivered EUR 804 million in sustainable savings to date, with plans for further savings in the coming years [9][26] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2026 will be a transition year, with expectations of flat revenue growth largely due to changes in Value-Based Care's risk contracting [30][38] - The company anticipates regulatory headwinds impacting earnings development, particularly from the phasing out of TDAPA benefits [33][35] - Management remains optimistic about achieving industry-leading growth and margins, targeting a compound annual growth rate of 3%-7% through 2028 [39][40] Other Important Information - The company initiated a EUR 1 billion share buyback program, reflecting a strengthened financial profile and commitment to returning excess cash to shareholders [6][11] - Operating cash flow for 2025 was EUR 2.7 billion, demonstrating strong cash generation capabilities [10] Q&A Session Summary Question: Key drivers of EBIT growth acceleration - Management indicated that the flat 2026 outlook is due to investment in HDF and systems platforms, with underlying operational work focused on improving business growth and revenue cycle management [45][46] Question: Impact of China tender modifications - Management confirmed a EUR 50 million EBIT impact in 2025 from regulatory changes in China, expecting a lower impact in 2026 while maximizing local strategies [49][50] Question: Phosphate binder expectations for 2026 - Management confirmed a EUR 220 million contribution in 2025, with expectations of a reduction in 2026 due to regulatory changes [53][57] Question: ACA subsidy headwinds - Management quantified ACA headwinds at around EUR 50 million for 2026, with ongoing assessments to be updated as the situation evolves [56][57] Question: Patient volume development and insurance requirements - Management expressed caution regarding patient volume growth, emphasizing the need to monitor flu season impacts and open enrollment outcomes [64][66] Question: U.S. dialysis volume recovery prerequisites - Management noted that Q1 is challenging for volume predictions, with expectations for gradual improvements over time driven by quality initiatives [80][82] Question: FME25 program costs and benefits - Management acknowledged front-loading costs in 2026, with higher savings contributions expected in 2027 as the program progresses [83][84]

Financial Data and Key Metrics Changes - Fresenius Medical Care achieved a group margin of 11.3% for 2025, driven by all three operating segments, landing within the target margin band for the year [6][7] - Operating income growth for 2025 reached 27%, marking a significant increase compared to previous years [7][12] - The company reported a strong organic revenue growth of 8% in Q4 2025, with earnings growth of 53%, resulting in a margin of 13.9%, a 430 basis points increase year-over-year [12][18] Business Line Data and Key Metrics Changes - Care Delivery in the U.S. experienced flat same-market treatment growth due to pressures from flu-related elevated mortality and mistreatments [12][14] - Care Delivery international markets delivered a solid 1.7% same-market treatment growth, supported by favorable U.S. rate and payer mix developments [13] - Value Based Care achieved a break-even operating income in 2025, a notable improvement from a historically loss-making position, with a 42% organic revenue growth in Q4 [15][22] Market Data and Key Metrics Changes - The company faced regulatory pressures in China, impacting Care Enablement revenue, which decreased by 3% due to volume-based procurement and stricter tender requirements [16][23] - The TDAPA regulation contributed approximately EUR 220 million to the Care Delivery segment in 2025, significantly aiding revenue despite higher medical benefit costs [14][21] Company Strategy and Development Direction - Fresenius Medical Care launched its new 2030 strategy, FME Reignite, aimed at accelerating growth and driving profitability improvements, with a focus on innovation [5][6] - The company is transitioning to a more streamlined clinic footprint, reducing its international clinic count from 49 to 25 core markets, enhancing operational efficiency [10][26] - The rollout of the 5008X CAREsystem is a key strategic initiative, expected to improve patient outcomes and operational efficiencies in U.S. clinics [6][28] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2026 will be a transition year, with expectations of flat revenue growth largely due to changes in Value Based Care's risk contracting [30][38] - The company anticipates a margin range of 10.5%-12% at the group level for 2026, while targeting to maintain enhanced profitability amidst regulatory headwinds [30][39] - Management expressed confidence in achieving industry-leading growth and margins, with a compound annual growth rate target of 3%-7% through 2028 [39][40] Other Important Information - The company executed a EUR 1 billion share buyback program, repurchasing shares worth EUR 586 million in 2025, which supported EPS growth [6][11] - Operating cash flow for 2025 was EUR 2.7 billion, demonstrating strong cash generation capabilities [10][24] Q&A Session Summary Question: Key drivers of EBIT growth acceleration - Management indicated that operational improvements and the impact of regulatory changes will influence EBIT growth, with a focus on underlying operational work and revenue cycle improvements [45][46] Question: Impact of China tender modifications - Management confirmed a EUR 50 million EBIT impact from regulatory changes in China for 2025, expecting a lower impact in 2026 while maximizing local strategies [49][50] Question: Phosphate binder contribution and expectations - Management confirmed a EUR 220 million contribution from phosphate binders in 2025, with expectations of a reduction in 2026 due to regulatory changes [53][57] Question: ACA subsidy headwinds - Management outlined regulatory effects of EUR 150 million-EUR 200 million, including ACA headwinds, with a specific quantification of around EUR 50 million for ACA [56][57] Question: U.S. volume trends and patient mix - Management emphasized a cautious approach to volume growth assumptions, with a focus on improving patient outcomes and quality initiatives [64][66] Question: FME25 program costs and benefits - Management acknowledged front-loading costs in 2026, with a higher savings contribution expected in 2027 as the program progresses [80][83]

Financial Data and Key Metrics Changes - Fresenius Medical Care achieved a group margin of 11.3% for 2025, driven by all three operating segments, landing within the target margin band for the year [6][10] - Operating income growth reached 27%, marking the top end of the financial outlook for the year [7] - The company reported a significant increase in earnings growth of 53% in Q4, resulting in a margin of 13.9%, a 430 basis points increase year-over-year [13][19] Business Line Data and Key Metrics Changes - Care Delivery in the U.S. experienced flat same-market treatment growth, while international markets delivered 1.7% growth [13][14] - Value-Based Care achieved a break-even operating income for 2025, a notable improvement from a loss of EUR 28 million in 2024 [22] - Care Enablement revenue decreased by 3%, primarily due to regulatory pressures in China, but continued to see positive pricing contributions [23] Market Data and Key Metrics Changes - The U.S. market faced pressures from elevated medical benefit costs and lower volumes, impacting overall performance [7][14] - In China, regulatory policies and volume-based procurement negatively impacted revenue and earnings development [17][23] - The company expects a headwind from the phasing out of TDAPA regulations in 2026, which will affect revenue recognition [30][33] Company Strategy and Development Direction - Fresenius Medical Care launched its new 2030 strategy, FME Reignite, aimed at accelerating growth and improving profitability [5] - The company is focusing on the rollout of the 5008X CAREsystem, which is expected to enhance patient outcomes and operational efficiencies [28][39] - The FME25+ transformation program has delivered EUR 804 million in sustainable savings, exceeding targets and positioning the company for future growth [10][26] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by regulatory headwinds and elevated costs but remains committed to maintaining profitability while investing in future growth [30][39] - The outlook for 2026 anticipates broadly flat revenue growth, reflecting changes in Value-Based Care's risk contracting [30][33] - Management expressed confidence in achieving industry-leading growth and margins, with a target of 3%-7% compound annual growth rate through 2028 [38][39] Other Important Information - The company initiated a EUR 1 billion share buyback program, reflecting a strengthened financial profile and commitment to returning excess cash to shareholders [6][12] - A proposed dividend of EUR 1.49 for 2025 represents a 3% increase from 2024, aligning with the target payout ratio of 30%-40% [12] Q&A Session Summary Question: Key drivers of EBIT growth acceleration and impact of same-market treatment growth - Management indicated that 2026 is a year of investment, with flat growth expected due to regulatory impacts, but operational improvements are anticipated to drive future growth [46][48] Question: Impact of China tender modifications and outlook for 2026 - Management confirmed a EUR 50 million EBIT impact from China in 2025, expecting a lower impact in 2026 as they adapt to regulatory changes [49][50] Question: Clarification on phosphate binder contributions and expectations for 2026 - Management confirmed a EUR 220 million contribution in 2025, with expectations of a reduction in 2026 due to regulatory changes [53][56] Question: Thoughts on ACA subsidy headwinds moving to 2027 and 2028 - Management quantified ACA headwinds at around EUR 50 million and indicated ongoing assessments for future impacts [55][56] Question: Impact of higher insurance requirements on patient volume - Management acknowledged the importance of monitoring patient mix and enrollment trends, emphasizing a cautious approach to volume growth expectations [62][66]